TSMHT
TEVA icon

Thurston Springer Miller Herd & Titak’s Teva Pharmaceuticals TEVA Stock Holding History

Thurston Springer Miller Herd & Titak’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-174
Closed -$2.92K – 1274
2025
Q2 		$2.92K Hold
174
– – ﹤0.01% 1373
2025
Q1 		$2.67K Buy
+174
New +$3.11K ﹤0.01% 1398
2024
Q4 		– Sell
-9,618
Closed -$173K – 1383
2024
Q3 		$173K Buy
9,618
+211
+2% +$3.69K 0.05% 314
2024
Q2 		$153K Buy
+9,407
New +$145K 0.05% 345

Other funds holding TEVA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PC
PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return

Thurston Springer Miller Herd & Titak's TEVA Position: Q3 2025 in Review

Thurston Springer Miller Herd & Titak sold out of Teva Pharmaceuticals (TEVA) in Q3 2025, closing a stake of 174 shares — an estimated $2.92K sold.

Thurston Springer Miller Herd & Titak first reported a position in TEVA in Q2 2024 and held it in 4 quarters. The position peaked at $173K in Q3 2024. 550 funds tracked by Wall St. Rank hold TEVA as of Q3 2025.

  • Thurston Springer Miller Herd & Titak reported no remaining Teva Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Thurston Springer Miller Herd & Titak sold 174 Teva Pharmaceuticals shares in Q3 2025, an estimated $2.92K.
  • Thurston Springer Miller Herd & Titak first reported a position in Teva Pharmaceuticals in Q2 2024 and held it in 4 quarters.
  • Thurston Springer Miller Herd & Titak's Teva Pharmaceuticals position peaked at $173K in Q3 2024.
  • 550 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q3 2025.

Based on Thurston Springer Miller Herd & Titak's 13F filing for Q3 2025, filed 7 Oct 2025.